Screener
Arcutis Biotherapeutics, Inc. ARQT Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 267,958 | 243,494 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 12 | 12 |
| Additional paid-in capital | 1,355,593 | 1,327,595 |
| Accumulated other comprehensive income (loss) | (656) | (44) |
| Accumulated deficit | (1,134,370) | (1,138,084) |
| Total stockholders’ equity | 220,579 | 189,479 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s common stock?
- Arcutis Biotherapeutics, Inc. (ARQT) reported common stock of 300M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s common stock changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 300M to 300M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s common stock has grown at a 0.0% compound annual growth rate (CAGR), from 300M to 300M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Arcutis Biotherapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude